AP
KDNY

AHL Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

AHL Partners’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-13,530
Closed -$1.9M – 845
2015
Q4 		$1.9M Buy
13,530
+10,918
+418% +$1.48M 0.15% 264
2015
Q3 		$253K Sell
2,612
-4,942
-65% -$589K 0.04% 611
2015
Q2 		$1.15M Buy
+7,554
New +$1.25M 0.05% 523

Other funds holding KDNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

AHL Partners's KDNY Position: Q1 2016 in Review

AHL Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2016, closing a stake of 13,530 shares — an estimated $1.9M sold.

AHL Partners first reported a position in KDNY in Q2 2015 and held it in 3 quarters. The position peaked at $1.9M in Q4 2015. 89 funds tracked by Wall St. Rank hold KDNY as of Q1 2016.

  • AHL Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • AHL Partners sold 13,530 Chinook Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $1.9M.
  • AHL Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • AHL Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $1.9M in Q4 2015.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2016.

Based on AHL Partners's 13F filing for Q1 2016, filed 16 May 2016.